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USP15 is a deubiquitinase that negatively regulates
activation of naive CD4+ T cells and generation of
IFN-g-producing T helper 1 (Th1) cells. USP15 defi-
ciency in mice promotes antitumor T cell responses
in a transplantable cancer model; however, it has
remained unclear how deregulated T cell activation
impacts primary tumor development during the
prolonged interplay between tumors and the im-
mune system. Here, we find that the USP15-deficient
mice are hypersensitive tomethylcholantrene (MCA)-
induced fibrosarcomas. Excessive IFN-g production
in USP15-deficient mice promotes expression of the
immunosuppressive molecule PD-L1 and the che-
mokine CXCL12, causing accumulation of T-bet+
regulatory T cells and CD11b+Gr-1+ myeloid-derived
suppressor cells at tumor site. Mixed bone marrow
adoptive transfer studies further reveals a T cell-
intrinsic role forUSP15 in regulating IFN-gproduction
and tumor development. These findings suggest that
T cell intrinsic USP15 deficiency causes excessive
production of IFN-g, which promotes an immuno-
suppressive tumor microenvironment during MCA-
induced primary tumorigenesis.INTRODUCTION
Cancer development involves dynamic interactions between tu-
mor cells and the immune system, and a hallmark of tumors is
their ability to evade immune surveillance (Dunn et al., 2004;
Schreiber et al., 2011). Despite the infiltration of tumor-specific2470 Cell Reports 13, 2470–2479, December 22, 2015 ª2015 The Aueffector T cells at tumor site, these immune cells are largely
ineffective in suppressing tumor growth. A common mechanism
of immune evasion for most tumors is the establishment of an
immunosuppressive microenvironment, composed of infiltrating
T cells and innate immune cells in addition to the proliferating
tumor cells and tumor stroma (Gajewski et al., 2013; Radoja
et al., 2000; Whiteside, 2008; Zou, 2005). Tumor cells produce
immunosuppressive factors, such as the ligand of the co-inhibi-
tory receptor PD1, PD-L1, which suppress effector T function
and promote the expansion of regulatory T (Treg) cells (Gajewski
et al., 2013; Whiteside, 2008). Tumor cells also secrete soluble
factors, such as cytokines and chemokines, which mediate
recruitment of Treg cells and myeloid-derived suppressor cells
(MDSCs), thereby facilitating the establishment of the immuno-
suppressive tumor microenvironment (Kitamura et al., 2015). It
has been thought that immune cells have paradoxical roles in
regulating cancer development. While immune cells mediate
cancer immune surveillance, they also contribute to the forma-
tion of tumor microenvironment and promote tumor growth (Gri-
vennikov et al., 2010; Whiteside, 2008).
Interferon-g (IFN-g), produced by effector T cells and innate
immune cells, is known as a cytokine that promotes innate and
adaptive immune responses against microbial infections and
tumor development (Dunn et al., 2006). IFN-g regulates the dif-
ferentiation and effector function of different types of immune
cells and also inhibits the growth and survival of cancer cells
(Zaidi andMerlino, 2011). However, the role of IFN-g in regulating
antitumor immunity appears to be complex and paradoxical,
showing both anti- and pro-tumorigenic functions (Wilke et al.,
2011; Zaidi et al., 2011; Zaidi andMerlino, 2011). Themechanism
underlying the two faces of IFN-g function in antitumor immunity
is incompletely understood, but IFN-g appears to have different
functions during different stages of tumor development. While
IFN-g is important for cancer immune destruction during the
elimination phase in the model of tumor immunoediting, IFN-gthors
Figure 1. IFN-g-Responsive Gene Signature
in Usp15/ Tumor Environment
(A) Frequency of tumor-free mice in the wild-type
(WT) and Usp15/ (KO) mice injected with two
different doses of MCA (400 or 800 mg).
(B) ELISA of the indicated cytokines in the serum of
wild-type and Usp15/ mice injected with two
different doses (400 and 800 mg) MCA. The serum
was collected from the mice that had developed a
palpable tumor (over 25 mm2) on day 150 after
injection of 400 or 800 mg MCA.
(C) qRT-PCR analysis of sorted CD45– cells in the
tumor from tumor-bearing wild-type and Usp15/
mice.
(D and E) Flow cytometric analysis of PD-L1 (D)
and CXCL12 (E) of CD45– cells in the tumor
from tumor-bearing wild-type and Usp15/ mice.
Shaded histogram represents isotype control
(D and E).
(F and G) Frequency of tumor-free mice in
Usp15/ mice treated with either a control anti-
body (Ctrl Ab) or neutralizing antibodies for PD-L1
(F) and CXCL12 (G) weekly from day 90 to day 146
after injection of 400 mg MCA.
Data are representative of four (A–E) or three
(F and G) independent experiments with ten mice (A, B, F, and G) or five mice (C–E) per group. Significance was determined by Mantel-Cox test (A, F, and G)
or two-tailed Student’s t test (B–E) (*p < 0.05; **p < 0.01). Data are presented as mean ± SEM. See also Figure S1.also contributes to the subsequent cancer immune evasion by
promoting expression of tolerant molecules, such as PD-L1
and indoleamin-2,3-dioxygenase 1 (IDO1), and recruitment of
Treg cells to tumor microenvironment (Schreiber et al., 2011;
Spranger et al., 2013).
T cells, particularly the IFN-g-producing CD4+ T helper 1 (Th1)
and CD8+ effector T cells, are key components of the immune
system for tumor surveillance and destruction (Kennedy and
Celis, 2008; Klebanoff et al., 2006). Under physiological condi-
tions, T cell activation is subject to tight regulation by various
negative factors, which prevents abnormal T cell responses
and autoimmunity. We have recently identified a deubiquitinase,
USP15, which functions as a negative regulator of T cell receptor
(TCR) signaling in CD4+ T cells. USP15 deficiency promotes the
activation of naive CD4+ T cells and their subsequent differenti-
ation into the IFN-g-producing Th1 cells (Zou et al., 2014).
Although USP15 does not have a cell-intrinsic role in regulating
CD8+ T cells, the USP15 deficiency also promotes CD8+ T cell
responses in vivo, likely due to stronger helper function of Th1
cells. Compared to wild-type control mice, the USP15-deficient
micemount stronger T cell responses to tumor growth in a trans-
plantable melanoma model, emphasizing the role of T cells in
antitumor immunity (Zou et al., 2014). However, since the devel-
opment of primary tumors involves a long period of interplays be-
tween tumors and the immune system, it has remained unclear
how the excessive and chronic production of IFN-g by USP15-
deficient T cells impacts the development of primary tumors.
To address this question, we employed a well-characterized
model of chemical-induced tumorigenesis: the methylcholan-
trene (MCA)-induced fibrosarcoma (Swann et al., 2008). Interest-
ingly, the USP15 deficiency profoundly enhanced the incidence
of MCA-induced fibrosarcoma, coupled with excessive pro-
duction of IFN-g and an IFN-g-responsive gene signature inCell Reptumor microenvironment. We further demonstrated that the
T cell-intrinsic IFN-g hyper-production in USP15-deficient mice
promoted formation of an immunosuppressive tumor microenvi-
ronment along with MCA-induced primary tumorigenesis.
RESULTS
IFN-g-Responsive Gene Signature in the Usp15/
Tumor Microenvironment
To examine the role of USP15 in regulating primary tumor for-
mation, we employed the MCA-induced fibrosarcoma model
of chemically induced tumorigenesis. We treated the wild-type
and Usp15/ mice with different doses of MCA and monitored
tumor formation for up to 200 days. At both low and high doses of
MCA treatment, theUsp15/mice developed fibroscomas with
a significantly higher incidence compared to wild-type mice (Fig-
ure 1A). TheUsp15/mice also had amore rapid onset of tumor
formation than the wild-type control mice (Figure 1A). These
results demonstrate that the Usp15/ mice are more sensitive
to the formation of MCA-induced fibrosarcomas.
To assess the mechanism by which USP15 regulates MCA-in-
duced tumorigenesis, we analyzed the concentration of several
major cytokines in the serum of the MCA-treated mice. While
the wild-type and Usp15/ mice had comparable levels of
most serum cytokines analyzed, the Usp15/ mice displayed
a profound increase in the level of serum IFN-g when treated
with both low and high doses MCA (Figure 1B). A hallmark of tu-
mors is the establishment of an immunosuppressive microenvi-
ronment, thereby evading immune surveillance (Gajewski et al.,
2013; Whiteside, 2008). Although IFN-g is generally considered
as an antitumor immune mediator, it also induces the expres-
sion of immunosuppressive genes in tumor microenvironment
(Zaidi and Merlino, 2011). Because of the excessive productionorts 13, 2470–2479, December 22, 2015 ª2015 The Authors 2471
Figure 2. T-bet+ Regulatory T Cells Were
Primed in the Tumor-Bearing Usp15/
Mice
(A) Flow cytometry analysis of Treg cells in TILs
from tumor-bearing wild-type (WT) and Usp15/
(KO) mice, showing a representative plot (left) and
summary graph of five mice (right).
(B) Flow cytometry analysis of CXCR4 of
tumor-infiltrating CD4+Foxp3+ cells in the tumor-
bearing wild-type and Usp15/ mice. Splenic
CD4+Foxp3+ cells were used as control (shaded
histogram).
(C) Flow cytometry analysis of tumor-infiltrating
CD4+Foxp3+ cells in the tumor-bearing Usp15/
mice treated with an anti-CXCL12 neutralizing
antibody weekly from day 90 to day 146 after in-
jection of 400 mg MCA.
(D) Intracellular T-bet staining of Foxp3+CD4+
regulatory T cells in the TILs from tumor-bearing
wild-type and Usp15/ mice. Shaded histogram
represents isotype control.
(E) Flow cytometric analysis of T-bet expression in
CD4+CD25+ Treg cells from naive wild-type and
Usp15/micestimulatedwithanti-CD3/anti-CD28
in media containing IL-2 alone (shaded histograms)
or IL-2 plus IFN-g (open histograms) for 4 days.
(F) Tcrb/Tcrd/mice were injected with 2 3 105 OVA-expressing B16 cells at day 0. At day 6, mice were treated with PBS control (Ctrl), OT-I T cells, or OT-I
T cells plus CD4+CD25+ Treg cells sorted from lymph nodes of naive wild-type (WT) or Usp15-KO (KO) mice (left panel), or from draining lymph nodes of tumor-
bearing wild-type (WT) or Usp15-KO (KO) mice (right panel). Tumor growth was measured every 2 days. Note that the control group got discontinued on day 14,
since their tumors reached the limiting size.
(G) Proliferation assays, based on CFSE dilution, of OT-I T cells in the presence of the indicated ratios of CD4+CD25+ Treg cells sorted from tumor-bearing wild-
type (WT) or Usp15/ (KO) mice.
(H) Frequency of tumor-free mice in the Usp15/ mice treated with an anti-CD25 neutralizing antibody weekly from day 90 to day 146 after injection of
400 mg MCA.
Data are representative of three independent experiments with four mice (A–E and G) or ten mice (F and H) per group. Significance was determined by Mantel-
Cox test (H) or two-tailed Student’s t test (A, C, D, F, and G) (*p < 0.05; **p < 0.01). Data are presented as mean ± SEM. See also Figure S2.of IFN-g in Usp15/ mice, we performed qRT-PCR assays to
analyze gene expression in the CD45 cell population, including
tumor cells and other non-immune cells, of the MCA-induced
tumors. Interestingly, the CD45 cells of the Usp15/ tumors
displayed elevated expression of an IFN-g-responsive gene
signature (Tbx21, Pd-l1, Irf1, Ido1, Cxcl5, and Cxcl12), most
strikingly Pd-l1 and Cxcl12, whereas the expression of inter-
leukin-4 (IL-4)-responsive genes (Gata3 and Ccl24) was compa-
rable between wild-type and Usp15/ CD45 cells (Figure 1C).
The elevated expression of PD-L1 and CXCL12 in the Usp15/
CD45– cells was also detected at the level of protein by flow cy-
tometry assays (Figures 1D and 1E).
To determine the functional significance of the aberrant
expression of PD-L1 and CXCL12 in promoting MCA-induced
tumor development in Usp15/ mice, we injected the MCA-
challenged mice with neutralizing antibodies for PD-LI or
CXCL12. The PD-L1 antibody significantly reduced the inci-
dence of MCA-induced tumors in both wild-type and Usp15/
mice (Figures 1F and S1). However, this phenotype was much
more striking for theUsp15/mice, consistent with the elevated
PD-L1 expression in the tumor microenvironment of these
mutant mice. Treatment of the Usp15/ mice with the anti-
CXCL12 antibody also reduced the tumor incidence (Figure 1G).
These data suggest that altered tumor microenvironment,
including aberrant expression of PD-L1 and the chemokine2472 Cell Reports 13, 2470–2479, December 22, 2015 ª2015 The AuCXCL12, contributes to the enhanced tumorigenesis in MCA-
treated Usp15/ mice.
Accumulation of T-bet+ Treg Cells in the Tumor
Microenvironment of Usp15–/– Mice
Foxp3+CD4+ Treg cells promote tumor formation and progres-
sion by inhibiting antitumor responses and mediating tumor
immune escape (Zou, 2006). To further elucidate the mechanism
bywhich USP15 regulatesMCA-induced primary tumorigenesis,
we analyzed the abundance and function of Treg cells at the
tumor site of wild-type and Usp15/ mice. Under tumor-free
conditions (injected with solvent control), the wild-type and
Usp15/mice had a similar frequency of Treg cells in the drain-
ing lymph node (Figure S2A). However, the tumor-bearing
Usp15/mice had a significantly higher frequency and absolute
number of Treg cells than the wild-type mice in both the tumor
and draining lymph node (Figures 2A and S2B). This phenotype
was not seen in the spleen, in which the wild-type and mutant
mice had comparable levels of Treg cells (Figure S2C), suggest-
ing increased recruitment or generation of Treg cells at tumor site
of the Usp15–/– mice.
We noted that tumor-infiltrating Treg cells expressed a higher
level of CXCR4 than splenic Treg cells in both wild-type and
Usp15–/– mice (Figure 2B). CXCR4 is a receptor of the chemokine
CXCL12, which has been implicated in the regulation of Treg cellthors
Figure 3. Excessive Accumulation of
MDSCs in Tumor-Bearing Usp15-KO Mice
(A) Flow cytometry analysis of Gr-1+CD11b+
cells in the tumor of tumor-bearing wild-type
(WT) and Usp15–/– (KO) mice. Data are pre-
sented as a representative plot of MDSC fre-
quency.
(B) Summary graph of MDSC absolute numbers in
indicated tissues based on five pairs of mice.
(C) Flow cytometry analysis of CXCR4 of tumor-
infiltrating Gr-1+CD11b+ cells in the tumor-
bearing wild-type and Usp15-KO mice. Splenic
Gr-1+CD11b+ cells were used as control (shaded
histogram).
(D) Flow cytometry analysis of Gr-1+CD11b+ cells
in the tumor of the tumor-bearing Usp15-KOmice treated with anti-CXCL12 neutralizing antibodies weekly from day 90 to day 146 after injection of 400 mgMCA.
(E) Tcrb/Tcrd/mice were injected with 2 3 105 OVA-expressing B16 cells. On day 6, mice were injected with PBS control (Ctrl), OT-I T cells, or OT-I T cells
plus Gr-1+CD11b+ cells sorted from the tumor in the tumor-bearing wild-type and Usp15-KO mice. Tumor growth was measured every 2 days.
(F) Proliferation assays, based on CFSE dilution, of CFSE-labeled OT-I T cells cultured either alone or together with MDSCs (3:1) sorted from tumors of wild-type
or Usp15-KO mice.
Data are representative of three independent experiments with at least four mice per group. Significance was determined by two-tailed Student’s t test (B and D)
(*p < 0.05). Data are presented as mean ± SEM. See also Figure S2.recruitment to the tumor site (D€urr et al., 2010). Because of the
elevated expression of CXCL12 in Usp15/ tumor microenvi-
ronment (Figures 1C and 1E), we examined the possible involve-
ment of the CXCL12/CXCR4 axis in Treg accumulation in the
tumor microenvironment of Usp15/ mice. Antibody-mediated
CXCL12 blockade reduced the frequency and absolute numbers
of Treg cells in the tumor of Usp15/ mice (Figure 2C). These
results suggest that deregulated expression of the chemokine
CXCL12 contributes to the abnormal Treg cell accumulation at
the tumor site of Usp15/ mice.
Recent evidence suggests that Treg cells display dynamic
expression of the transcription factors T-bet and GATA-3, which
are important for Treg-mediated immune tolerance (Yu et al.,
2015). Of note, the expression of T-bet and GATA-3 can be stim-
ulated by IFN-g and IL-4, respectively. We found that Treg cells
from the tumor and tumor-draining lymph node of Usp15/
mice expressed a higher level of T-bet, although not GATA3,
than the Treg cells from wild-type mice (Figures 2D and S2D;
data not shown). This phenotype appeared to be specific for tu-
mor microenvironment, since splenic Treg cells of the Usp15/
andwild-typemice had a comparable level of T-bet (Figure S2D).
The USP15 deficiency did not alter the sensitivity of Treg cells
to IFN-g-induced T-bet expression, suggesting that excessive
IFN-g production contributed to the enhanced T-bet+ Treg cells
in Usp15/ tumor environment (Figure 2E).
We next examined the immunosuppressive function of the
USP15-deficient Treg cells using an in vivo model involving inoc-
ulation of the T cell-deficient Tcrb/Tcrd/mice with OVA-ex-
pressing B16 melanoma cells and subsequent adoptive transfer
of the OVA-specific OT-I T cells along with either wild-type or
USP15-deficient Treg cells from tumor-bearing or naive mice.
Overall, the Treg cells derived from tumor-bearing mice dis-
played stronger suppressive function than those derived from
naive mice (Figure 2F). Furthermore, while the wild-type and
USP15-deficient Treg cells from naive mice displayed similar
levels of suppressive function, the USP15-deficient Treg cells
were significantly more suppressive than the wild-type TregCell Repcells when they were isolated from tumor-bearing mice (Fig-
ure 2F). These results were consistent with the upregulated
T-bet expression in Usp15/ Treg cells under tumor-bearing
conditions (Figure 2D). The Treg cells from USP15-deficient tu-
mor-bearing mice also more potently inhibited the proliferation
of native T cells in vitro than Treg cells from wild-type tumor-
bearing mice (Figure 2G). Moreover, Treg cell downregulation
by a neutralizing anti-CD25 antibody significantly reduced the
incidence of tumor formation in Usp15/ mice (Figure 2H),
whereas the anti-CD25 antibody only slightly decreased the inci-
dence of MCA-induced tumors in wild-type mice (Figure S2E).
Taken together, these results suggest that recruitment and in-
duction of T-bet+ Treg cells contributes to the enhanced tumor
formation in Usp15/ mice.
USP15 Regulates MDSC Recruitment to Tumor
Environment
In addition to Treg cells, MDSCs, characterized by high levels of
surface Gr-1 and CD11b, play an important role in maintaining
immunosuppressive tumor microenvironment and promoting tu-
mor growth (Nagaraj and Gabrilovich, 2008). MDSC expansion
and recruitment to tumor site are induced by inflammatory cyto-
kines and chemokines secreted by immune cells and tumor cells
(Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and Sinha,
2009; Umansky and Sevko, 2013). In particular, both IFN-g and
the chemokine CXCL12 have been implicated in the induction
of MDSC accumulation in tumor tissues (Umansky and Sevko,
2013). Because of the excessive production of IFN-g by T cells
and upregulation of CXCL12 in tumor tissues of the Usp15/
mice, we analyzed the abundance of MDSCs at the tumor site
of wild-type and Usp15/ mice. The tumor tissue of Usp15/
mice contained a profoundly higher frequency and number of
the Gr-1+CD11b+ MDSCs than the tumor tissue of the wild-
type mice (Figures 3A and 3B). Similarly, a significant increase
in the frequency and number of MDSCs was detected in
the tumor-draining lymph node, although not in the spleen, of
Usp15/ mice (Figures 3B, S2F, and S2G).orts 13, 2470–2479, December 22, 2015 ª2015 The Authors 2473
Figure 4. Excessive IFN-gContributes to the
Formation of Immunosuppressive Tumor
Microenvironment in Usp15–/– Mice
Tumor-bearing Usp15–/– (KO) mice were treated
with either a control (Ctrl) IgG1 antibody or an
anti-IFN-g neutralizing antibody weekly from day
90 to day 146 after injection of 400 mg MCA. The
treated mice were subjected to the following
studies.
(A) qRT-PCR analysis of the indicated genes in
sorted CD45– non-immune cells.
(B and C) Flow cytometry analysis of PD-L1 (B) and
CXCL12 (C) in CD45– non-immune cells. Shaded
histogram represents isotype control (B and C).
(D) Flow cytometry analysis of tumor-infiltrating
CD4+Foxp3+ Treg cells, presented as a represen-
tative plot of Treg frequency (left) and a summary
graph of Treg absolute numbers (right).
(E) Intracellular T-bet staining of Foxp3+CD4+ Treg cells in the TILs, showing a representative plot (left) and a summary graph of mean fluorescence intensity (MFI,
right). Shaded histogram represents isotype control.
(F) Flow cytometry analysis of Gr-1+CD11b+ MDSCs in the tumor from antibodies-treated mice.
(G) Frequency of tumor-free mice treated with indicated antibodies after MCA injection.
Data are representative of three independent experiments with at least four mice (A–F) or ten mice (G) per group. Significance was determined by Mantel-Cox
test (G) or two-tailed Student’s t test (A–F) (*p < 0.05; **p < 0.01). Data are presented as mean ± SEM.The tumor-infiltrating MDSCs (Gr-1+CD11b+ cells) of both the
wild-type and Usp15/ mice expressed high levels of the
CXCL12 receptor, CXCR4 (Figure 3C). Because of the elevated
expression of CXCL12 in the tumor of Usp15/mice, we exam-
ined the role of CXCL12 inmediatingMDSC recruitment to tumor
site. Indeed, injection of the tumor-bearing Usp15/ mice with
a CXCL12-neutralizing antibody, but not a control antibody,
substantially reduced the frequency and absolute number of
MDSCs in the tumor (Figure 3D). These data suggest that aber-
rant production of the chemokine CXCL12 contributes to the
accumulation of tumor-infiltrating MDSCs in the Usp15/mice.
Given that MDSCs have been implicated to suppress the
antitumor function of T cells (Umansky and Sevko, 2013), we
compared the immunosuppressive function of the MDSCs
(Gr-1+CD11b+ cells) derived from tumor-bearing wild-type and
Usp15/ mice. We used an adoptive transfer model involving
injection of T cell-deficient (Tcrb/Tcrd/) mice with OVA-
expressing B16 melanoma cells and subsequent transfer of
OVA-specific OT-I T cells along with sorted Gr-1+CD11b+ cells.
As expected, OT-I T cells efficiently inhibited B16 tumor growth
in the absence of MDSCs (Figure 3E). Furthermore, MDSCs
derived from wild-type and the USP15-deficient mice displayed
similar activities in suppressing the tumor-rejecting function of
OT-I T cells (Figure 3E). In an in vitro model of T cell prolifera-
tion assay, the wild-type and USP15-deficient MDSCs also dis-
played similar T cell-inhibitory function (Figure 3F). Thus, USP15
deficiency promotes the accumulation of MDSCs, although it
does not alter the T cell-suppressive activity of MDSCs.
IFN-gBlockade Disrupts the Immunosuppressive Tumor
Microenvironment
IFN-g is generally viewed as a cytokine that mediates antitumor
immunity, but it also has pro-tumorigenic functions (Zaidi et al.,
2011; Zaidi and Merlino, 2011). It has remained unclear how
excessive production of IFN-g impacts tumor microenvironment2474 Cell Reports 13, 2470–2479, December 22, 2015 ª2015 The Auduring MCA-induced tumorigenesis. We determined the role of
IFN-g in establishing the immunosuppressive tumor microen-
vironment of Usp15/ mice by administration of a neutralizing
anti-IFN-g antibody. Injection of the anti-IFN-g antibody, but
not a control immunoglobulin G1 (IgG1) antibody, efficiently in-
hibited the expression of IFN-g-associated gene signature,
particularly Pd-l1 and Cxcl12, in tumor tissues (Figure 4A). On
the other hand, the anti-IFN-g treatment did not alter the expres-
sion of several other genes, including those encoding the che-
mokines CCL1, CCL22, and CCL24 (Figure 4A). The IFN-g
neutralizing antibody also reduced the expression of PD-L1
and CXCL12 at the protein level (Figures 4B and 4C). Moreover,
IFN-g neutralization reduced the frequency and number of tu-
mor-infiltrating Treg cells (Figure 4D) and inhibited T-bet expres-
sion in Treg cells (Figure 4E). The abnormal Gr-1+CD11b+ cell
recruitment was also reversed in the presence of the IFN-g
neutralizing antibody (Figure 4F). The IFN-g blockade also
delayed the formation of MCA-induced fibrosarcomas in the
Usp15/ mice (Figure 4G). Compared to anti-PD-L1 and anti-
CD25, the anti-IFN-g antibody was less effective in tumor
inhibition. This result was likely due to the duel roles for IFN-g
in regulating antitumor immunity (Zaidi and Merlino, 2011).
Notwithstanding, these data reveal an essential role for aberrant
IFN-g signaling in promoting immunosuppressive microenviron-
ment formation.
T Cells Are a Major Source of Aberrant IFN-g Production
in Usp15–/– Mice
IFN-g is an inflammatory cytokine produced by Th1 subset of
CD4+ T cells and CD8+ T cells as well as by some innate immune
cells, including natural killer (NK) cells and macrophages (Ges-
sani and Belardelli, 1998; Kubota, 2010; Schoenborn and
Wilson, 2007). To determine the source of the aberrantly higher
level of serum IFN-g in Usp15/ mice, we examined whether
the USP15 deficiency promoted IFN-g production in T cells orthors
Figure 5. T Cells Serve as theMain Source of
Aberrant IFN-g in Tumor-Bearing Usp15-KO
Mice
(A–D) Intracellular staining and flow cytometry
analyses of the indicated cytokines in CD4+
or CD8+ T cells from draining lymph node
(A and B) or tumor (C and D) of tumor-bearing
wild-type (WT) and Usp15–/– (KO) mice. Data are
presented as representative plots of cell fre-
quencies (A and C) and summary graph of ab-
solute cell numbers based on five pairs of mice
(B and D).
(E) qRT-PCR analysis of Ifng mRNA of sorted
NK (CD3–NK1.1+) cells and macrophages (F4/
80+CD11b+) in the spleen (Spl) or TILs of tumor-
bearing wild-type and Usp15-KO mice.
(F and G) Intracellular staining and flow
cytometry analysis of IFN-g in the splenocytes
(Spl) or TILs from tumor-bearing wild-type
and Usp15–/– mice treated (i.p.) with 200 mg LPS
for 6 hr.
(H) qRT-PCR analysis of Ifna and Ifnb mRNA of
DCs (CD11c+MHC-II+) sorted from lymph nodes of
naive wild-type and Usp15/ mice or draining
lymph nodes of tumor-bearing (Tumor) wild-type
and Usp15/ mice.
Data are representative of five (A–D) or three (E–H) independent experiments with at least four mice per group. Significance was determined by
two-tailed Student’s t test (B and D) (*p < 0.05). Data are presented as mean ± SEM. See also Figure S3.innate immune cells at the tumor site. In the spleen, the fre-
quency and absolute numbers of the IFN-g-producing Th1 and
CD8+ T cells, as well as other T cell subsets, were similar be-
tween wild-type and Usp15/ mice (Figures S3A and S3B).
However, in the tumor-draining lymph node, the Usp15/
mice had a significantly higher frequency and absolute number
of IFN-g-producing CD4+ and CD8+ T cells, whereas the fre-
quency and absolute number of IL-4-producing Th2 and IL-17-
producing Th17 cells were comparable between the wild-type
andUsp15–/– mice (Figures 5A and 5B). Similarly, the tumor-infil-
trating lymphocytes (TILs) of Usp15/ mice contained a
profoundly higher level of IFN-g-producing Th1 and CD8+
T cells (Figures 5C and 5D). Moreover, the aberrant activation
of Th1 and CD8+ T cells in the Usp15/ mice was specifically
caused by tumorigenesis, since the control (injected with oil)
wild-type and Usp15/ mice had similar frequency and abso-
lute numbers of IFN-g-producing CD4+ or CD8+ T cells in the
draining lymph node (Figures S3C and S3D).
We next examined IFN-g production in innate immune cells.
Compared to splenic NK cells (CD3–NK1.1+), the tumor-infil-
trating NK cells displayed a much higher level of Ifng gene
expression, as determined by qRT-PCR assays (Figure 5E).
However, this phenotype was seen in both wild-type and
USP15-deficient NK cells. The wild-type and USP15-dericient
NK cells were also comparable in IFN-g expression upon
in vitro stimulation with LPS (Figures 5F and 5G). Furthermore,
USP15 deficiency also did not influence Ifng expression in tu-
mor-infiltrating or splenic macrophages (F4/80+CD11b+) (Fig-
ure 5E). Since dendritic cells are important for T cell activation
in antitumor immune responses, we next performed experiments
to compare the T cell stimulating function of wild-type and
Usp15/ dendritic cells (DCs). The wild-type and Usp15/Cell RepDCs, derived from the lymph nodes of naive or tumor-bearing
mice, did not show major differences in their capacity to stimu-
late naive T cell proliferation (Figure S3E). Moreover, DCs from
wild-type and Usp15/ tumor-bearing mice exhibited similar
levels of type I interferon expression (Figure 5H). These results
further emphasize the role of USP15 in regulating IFN-g expres-
sion in T cells.
USP15-Deficient T Cells Promote MCA-Induced
Tumorigenesis
Because of the association of aberrantly activated T cells with
enhanced tumorigenesis in the Usp15/ mice, we performed
mixed bone marrow adoptive transfer studies to directly
examine the T cell-specific role of USP15 in regulating MCA-
induced fibrosarcoma. We adoptively transferred the lympho-
cyte-deficient Rag1/mice with a mixture of bone marrow cells
derived from Usp15/ and Tcrb/Tcrd/mice and then chal-
lenged the recipient mice (hereafter called Usp15/ chimeric
mice) with MCA (Figure 6A). Since the Tcrb/Tcrd/ bone
marrow could generate all immune cells, except T cells, the
Usp15/ chimeric mice would contain USP15-deficient T cells
and wild-type innate immune cells, B cells, and non-immune
cells (including the tumor cells). As controls, we generated
bone marrow chimeric mice by transferring a mixture of wild-
type bone marrow and Tcrb/Tcrd/ bone marrow (hereafter
called wild-type chimeric mice). Under these conditions, the
Usp15/ chimeric mice were substantially more sensitive to
MCA-induced tumorigenesis than the wild-type chimeric mice,
as shown by both tumor incidence and tumor growth rate
(Figures 6B and 6C). As seen with Usp15/ mice (Figure 1B),
the Usp15/ chimeric mice had a significantly higher level of
serum IFN-g than that of the control chimeric mice (Figure 6D).orts 13, 2470–2479, December 22, 2015 ª2015 The Authors 2475
Figure 6. T Cell-Intrinsic Role of USP15
in Regulating MCA-Induced Fibrosarcoma
Formation
(A) Usp15-KO (KO) and wild-type (WT) mixed
bone-marrow chimeric mice were generated by
adoptive transfer of irradiated Rag1-KO mice with
Tcrb/Tcrd/ bone marrows mixed (in 4:1 ratio)
with bone marrows from Usp15-KO and wild-type
mice, respectively. The mice were injected with
MCA (400 mg) 31 days after bone marrow transfer.
(B) Frequency of tumor-free mice following MCA
injection of the WT and Usp15-KO bone marrow
chimeric mice indicated in (A).
(C) Tumor growth rates of the chimeric mice from
(B), presented as mm2/day.
(D) ELISA analysis of the indicated cytokines in the
serum collected from the mice described in (A)
with a palpable tumor (over 25 mm2) on day 150
after MCA injection.
(E and F) Intracellular staining and flow cytometry
analyses of IFN-g in CD4+ and CD8+ T cells iso-
lated from the draining lymph node (E) or TILs (F) of tumor-bearing wild-type and Usp15-KO mixed bone marrow chimeric mice described in (A).
Data are representative of three independent experiments with at least four mice (C–F) or tenmice (B) per group. Significance was determined byMantel-Cox test
(B) or two-tailed Student’s t test (C–F) (*p < 0.05). Data are presented as mean ± SEM. See also Figure S4.Furthermore, the Usp15/ chimeric mice had a greater level of
IFN-g-producing CD4+ and CD8+ T cells than wild-type chimeric
mice in the draining lymph nodes and tumor tissues, although not
in the spleen (Figures 6E, 6F, and S4A). The level of other T cell
subsets was comparable between the Usp15/ and wild-type
chimeric mice (Figures S4B and S4C). These results were remi-
niscent of those obtained with the Usp15/mice, thus suggest-
ing a T cell-intrinsic role for USP15 in regulating MCA-induced
T cell function and primary tumor formation.
USP15-Deficient T Cells Contribute to the
Immunosuppressive Tumor Microenvironment
To further assess the mechanism underlying the T cell-intrinsic
role of USP15 in regulating MCA-induced tumorigenesis, we
analyzed the effect of USP15 deficiency on the formation of
immunosuppressive tumor microenvironment using the mixed
bone marrow chimeric mice described above. The tumor of the
Usp15/ chimeric mice had upregulated expression of PD-L1
and CXCL12 (Figures 7A–7C). These chimeric mice also had a
higher frequency and absolute number of Foxp3+CD4+ Treg cells
in the draining lymph node and tumor, although not in the spleen
(Figures 7D, 7E, and S5A). As seen with the Usp15/ mice, the
USP15-deficient Treg cells derived from the Usp15/ chimeric
mice had an elevated level of T-bet expression (Figure 7F). More-
over, theUsp15/ chimeric mice displayed a higher percentage
and absolute number of MDSCs in the tumor, draining lymph
node, but not in the spleen, compared to the wild-type chimeric
mice (Figures 7G and S5B). Together, these adoptive transfer
experiments suggest a T cell-intrinsic role for USP15 deficiency
in promoting IFN-g production and immunosuppressive tumor
microenvironment formation.
USP15 Deficiency Promotes Immunity against
Transplanted MCA Tumors
Our previous work demonstrates that USP15 deficiency pro-
motes antitumor immunity in a transplantable B16 melanoma2476 Cell Reports 13, 2470–2479, December 22, 2015 ª2015 The Autumor model (Zou et al., 2014), which differs from the present
findings obtained using the MCA-induced primary tumor model.
This result is, however, not surprising, since transplantable tu-
mors bypass the cellular transformation phase of tumorigenesis
and trigger acute antitumor immune responses without involving
a long period of tumor-immune system interactions. However, it
is also possible that USP15 may have opposing roles in immune
responses against different types of tumors. To examine these
possibilities, we employed a transplantable tumor model using
a tumor cell line derived from the MCA-induced fibrosarcoma,
MCA-205. As seen with the B16 melanoma model, USP15
deficiency enhanced host defense against the transplanted
MCA tumors, leading to significantly smaller tumors in the
Usp15/ mice than in the wild-type mice (Figure S6A). Consis-
tently, theUsp15/mice had increased frequency and absolute
number of IFN-g-producing T cells infiltrating to the tumors
(Figure S6B). Likely due to the acute nature of the antitumor
immunity in the transplantable tumor model, the stronger T cell
response did not substantially alter the immunosuppressive
cell populations, since the MCA-205 tumors in wild-type and
Usp15/mice had similar frequency and absolute number of tu-
mor-infiltrating Treg cells and MDSCs (Figures S6C and S6D).
The wild-type and USP15-deficient Treg cells also expressed
similar levels of T-bet (Figure S6E). These findings indicate that
USP15 ablation promotes immunity against transplantable
MCA-205, as well as B16, tumors.
DISCUSSION
Cancer development involves dynamic interplays between tu-
mor and the immune system, with the immune system possess-
ing paradoxical functions (de Visser et al., 2006; Whiteside,
2008). Although the anti-tumorigenic function of the immune sys-
tem has been extensively studied, the pro-tumorigenic function
of immune cells has been incompletely understood. In particular,
whether chronic and excessive activation of IFN-g-producingthors
Figure 7. T Cell-Intrinsic Induction of IFN-g-
Responsive Gene Signature in the Tumor
Environment of Usp15-KO Mice
(A–C) qRT-PCR analysis of the indicated genes
(A) and flow cytometry analysis of PD-L1 (B) or
CXCL12 (C) in sorted CD45– non-immune cells
from tumor-bearing wild-type and Usp15-KO
mixed bone marrow chimeric mice described in
Figure 6A. Shaded histogram represents isotype
control (B and C).
(D and E) Flow cytometry analysis of Treg cells in
the draining lymph node and TILs of the tumor-
bearing wild-type and Usp15-KO mixed bone
marrow chimeric mice described in Figure 6A.
(F) Intracellular T-bet staining of Treg cells in the
draining lymph node (dLN) or TILs of the tumor-
bearing wild-type and Usp15-KO mixed bone
marrow chimeric mice described in Figure 6A.
(G) Flow cytometry analysis of Gr-1+CD11b+MDSCs in the tumor from the tumor-bearing wild-type and Usp15-KOmixed bone marrow chimeric mice described
in Figure 6A.
Data are representative of three independent experiments with at least four mice per group. Significance was determined by two-tailed Student’s t test (A–C and
E–G) (*p < 0.05; **p < 0.01). Data are presented as mean ± SEM. See also Figures S5 and S6.T cells inhibits or promotes tumorigenesis is incompletely under-
stood. In the present study, we demonstrated that ablation of
the T cell negative regulator, USP15, caused hyper-activation
of IFN-g-secreting T cells and increased the incidence of primary
tumor formation in the MCA fibrosarcoma primary tumor model.
The USP15-deficient T cells, likely via excessive production of
IFN-g, promoted an immunosuppressive tumor microenviron-
ment that suppressed antitumor immunity.
IFN-g is generally viewed as an inflammatory cytokine that
promotes cellular immunity against infections and tumor devel-
opment; however, accumulating evidence implicates IFN-g as
a cytokine with both anti- and pro-tumorigenic functions
(Zaidi and Merlino, 2011). We have previously shown that the
Usp15/mice mount stronger IFN-g+ T cell responses and anti-
tumor immunity than wild-type control mice in a transplantable
B16 melanoma model (Zou et al., 2014). Our present study
further demonstrated excessive IFN-g+ T cell responses of the
Usp15/ mice during MCA-induced primary fibrosarcoma
development. However, in contrast to their enhanced ability to
reject transplantable tumors, theUsp15/mice were more sen-
sitive to MCA-induced tumor formation. These opposing results
were not due to the differences betweenmelanoma and fibrosar-
coma, since theUsp15/mice also had stronger ability to reject
transplanted MCA-205 tumors than wild-type mice. We believe
that the seemingly controversial results are likely due to the ma-
jor differences in the formation of primary and transplantable
tumors (Dranoff, 2012). In particular, formation of transplantable
tumors bypasses the early steps of tumorigenesis. Although this
model is ideal for studying antitumor immunity against pre-
established tumors, it is unable to study the effect of immune
system on the early steps of tumor development, which typically
involves dynamic interplays between tumors and the immune
system and establishment of a complex tumor microenviron-
ment (Schreiber et al., 2011; Whiteside, 2008; Zou, 2005). Differ-
ences between primary and transplantable tumor models have
also been seen with other mouse models, such as mice lacking
the innate immune signaling adaptorMyD88 (Swann et al., 2008).Cell RepOur present study revealed that in the MCA-induced fibro-
sarcoma model, USP15 deficiency caused hyper-activation of
IFN-g+ T cells, which was associated with formation of a more
immunosuppressive tumor microenvironment characterized by
upregulated expression of PD-L1 and CXCL12 and enhanced
recruitment of Treg cells and MDSCs. Such phenotypes could
be reversed by downregulation of IFN-g function with a neutral-
izing anti-IFN-g antibody. These findings suggest that although
USP15 deficiency promotes antitumor T cell responses against
pre-established (transplanted) tumors, the chronic production
of excessive IFN-g inUsp15/micemay promote primary tumor
development through facilitating the establishment of immuno-
suppressive tumormicroenvironment.Mixedbonemarrowadop-
tive transfer experiments confirmed the T cell-intrinsic function of
USP15 in regulating IFN-g production and tumor microenviron-
ment formation, emphasizing a protumorigenic role for T cell-
derived IFN-g. However, it is important to note that our data could
not rule out the possibility that the function of USP15 in regulating
tumor microenvironment also involves additional mechanisms.
Nevertheless, the excessive production of IFN-g in Usp15/
mice appears to be one factor that contributes to the establish-
ment or maintenance of immunosuppressive tumor microenvi-
ronment in the MCA fibrosarcoma model of tumorigenesis.
Treg cells and MDSCs are major cellular components in the
tumormicroenvironment that inhibit antitumor immune responses
(Gajewski et al., 2013; Umansky and Sevko, 2013; Whiteside,
2008). Our data suggest that the chemokineCXCL12was respon-
sible for enhanced recruitment of Treg cells and MDSCs to tumor
site in Usp15/ mice. CXCL12 was upregulated in the tumor
microenvironment of Usp15/ mice in an IFN-g-dependent
manner, and antibody-mediated CXCL12 neutralization reduced
the frequency of Treg cells and MDSCs at tumor site. The exces-
sive production of IFN-g in Usp15/ mice also promoted the
effector functionof Tregcells,which involved inductionof the tran-
scription factorT-bet.TheT-bet+Tregcells areknown tobe impor-
tant for controlling the function of Th1 cells and, thereby, sup-
pressing Th1 cell-mediated inflammatory responses (Hall et al.,orts 13, 2470–2479, December 22, 2015 ª2015 The Authors 2477
2012; Koch et al., 2009, 2012). Our data suggest that these Treg
cells also potently suppress the effector function of CD8+ T cells
in antitumor immunity. The accumulation of T-bet+ Treg cells in
the tumor of Usp15/ mice was caused by loss of USP15 in
T cells and apparently due to the aberrant expression of IFN-g.
In summary, the present study confirmed our previous finding
that USP15 negatively regulates T cell responses to tumor for-
mation (Zou et al., 2014). However, the USP15-mediated T cell
regulation appears to have different roles in antitumor immunity.
On the one hand, USP15 deficiency enhances the ability of
T cells to reject pre-established tumors, as suggested by
work with transplantable tumor models (Zou et al., 2014; present
study). On the other hand, the aberrant activation of the USP15-
deficient T cells appears to promote an immunosuppressive tu-
mor microenvironment that facilitates tumor development during
the long period of tumor-immune system interplay. It is thus
possible that inhibition of USP15, along with targeting immuno-
suppressive regulators of the tumor microenvironment, may
induce strong antitumor immunity. While this possibility needs
to be examined by future studied, we have shown that in the
MCA-induced fibrosarcoma model, neutralizing antibodies for
PD-L1 and CXCL12 inhibit tumor formation more effectively in
Usp15–/– mice than in wild-type mice.
EXPERIMENTAL PROCEDURES
Mice
Usp15/ mice were generated using the OmniBank retroviral gene-trapping
technique (Taconic). The mice were originally in C57BL/6-129 mixed back-
ground and subsequently backcrossed for six generations to the C57BL/6
background. Heterozygous (Usp15+/–) mice were bred to generate age-
matched wild-type (Usp15+/+) and homozygous Usp15-KO (Usp15/) exper-
imental mice. Tcrb/Tcrd/ mice, Rag1/ mice, and OT-I TCR-transgenic
mice were obtained from Jackson Laboratory. Mice were maintained in spe-
cific pathogen-free facility, and all animal experiments were conducted in
accordance with protocols approved by the Institutional Animal Care and
Use Committee of the University of Texas MD Anderson Cancer Center.
Antibodies, Reagents, and Cell Lines
PE-conjugated anti-mouse CD274 (PD-L1, B7-H1) and other additional
antibodies for flow cytometry were from eBioscience as described. Mouse
CXCL12 (clone: 79014) neutralizing antibody was from R&D Systems. Rat
anti-mouse IFN-g (clone: XMG1.2), rat IgG1 isotype control (clone: HRPN),
rat anti-mouse CD25 (clone: PC-61.5.3), rat anti-mouse PD-L1 (clone:
10F.9G2), rat IgG2b isotype control (clone: LTF-2), and mouse IgG1 isotype
control (clone: MOPC-21) antibodies were from Bioxcell. 3-Methylcholan-
threne (MCA) was from Sigma-Aldrich. MCA-205 cell line was kindly provided
by Dr. Tomasz Zal (MD Anderson Cancer Center, TX).
MCA-Induced Fibrosarcoma
Induction of fibrosarcoma using the carcinogen MCA was essentially as
described (Swann et al., 2008). Wild-type and Usp15/mice were given sub-
cutaneous injection of low or high doses ofMCA (400 or 800 mg), as indicated in
the figure legends, on the right flank. The mice were monitored for the devel-
opment of fibrosarcomas weekly over the course of 200 days. Tumor size
was presented as a caliper square calculated based on two perpendicular
diameters (mm2). Mice with tumors larger than 225 mm2 were sacrificed and
recorded as lethal based on protocols approved by the Institutional Animal
Care and Use Committee of the University of Texas MD Anderson.
Isolation of TIL
Tumors were pressed and collected in complete RPMI 1640. After washing
(300 3 g, 10 min), cell suspensions were resuspended in complete RPMI2478 Cell Reports 13, 2470–2479, December 22, 2015 ª2015 The Au1640 containing collagenase IV (0.05%; Roche Applied Science) at 37C for
30–40min. After digestion, cell suspensions were passed through 70-mmnylon
cell strainers to yield single-cell suspensions. CD45+ cells (TILs) were sorted
for further analysis.
Flow Cytometry Analysis
Single-cell suspensions were made from spleens, draining lymph nodes, and
tumor tissues. These cells were stained with indicated specific conjugated
antibodies and subjected to flow cytometry, and cell sorting as described
using LSR II (BD Bioscience) and FACSAria (BD Bioscience) flow cytome-
ters, respectively. For intracellular cytokine staining (ICS), single-cell suspen-
sions were further stimulated for 4 hr with phorbol myristate acetate (PMA)
plus ionomycin in the presence of monensin and then subjected to intracel-
lular staining and flow cytometry. The data were analyzed using FlowJo
software.
ELISA and qRT-PCR
Serum was collected from the mice and then was analyzed by ELISA using a
commercial assay system (eBioscience). Total RNAwas extracted from sorted
CD45– cells from the tumor tissues. cDNAwas synthesized and then subjected
to qRT-PCR using gene-specific primers (Table S1).
Antibody-Mediated Neutralization
Mice were injected i.p. with 500 mg PD-L1 (clone: 10F.9G2), 100 mg CXCL12
(clone: 79014), 500 mg CD25 (clone: PC-61.5.3), or 500 mg IFN-g (clone:
XMG1.2) neutralizing antibodies. Injections were performed once a week for
8 weeks from day 90 to 146 after MCA injection. Control groups in PD-L1
neutralization experiments received rat IgG2b (clone: LTF-2); controls for
CXCL12 neutralization experiments received mouse IgG1 (clone: MOPC-21),
whereas controls in CD25 and IFN-g neutralization experiments received rat
IgG1 isotype control (clone: HRPN).
Adoptive T Cell Immunotherapy Model
Tcrb/Tcrd/ mice were injected subcutaneously with 2 3 105 B16 mela-
noma cells expressing a surrogate tumor antigen, OVA. At day 6 after tumor
injection, mice received an i.v. injection of PBS control, 1 3 106 OT-I CD8+
T cells, 1 3 106 OT-I CD8+ T cells plus 2 3 105 CD4+CD25+ T cells (Treg),
or 1 3 106 OT-I CD8+ T cells plus 2 3 105 Gr-1+CD11b+ cells (MDSC).
The challenged mice were monitored for tumor growth. Splenic OT-I CD8+
T cells were sorted from naive OT-I mice. Treg cells and MDSCs were sorted
from tumor-bearing wild-type and Usp15/ mice.
T Cell Proliferation Assays
Splenic OT-I CD8+ T cells were sorted from naive OT-I mice and labeled with
5 mM carboxyfluorescein succinimidyl ester (CFSE) for 10 min at 37C. 53 104
CFSE-labeled T cells were co-cultured with 1.5 3 105 splenocytes from naive
B6 mice and CD4+CD25+ T cells (Treg) or Gr-1+CD11b+ cells (MDSC) from the
tumor of tumor-bearing mice in the presence of 0.1 mg OVA257–264 peptide for
2 days. Cell proliferation was measured by flow cytometry based on CFSE
dilution.
Adoptive Transfer of Bone Marrow Cells
Bone marrow cells (1 3 106) isolated from Usp15/ or wild-type mice were
mixed with bone marrow cells (43 106) from Tcrb/Tcrd/mice (in 1:4 ratio)
and adoptively transferred into irradiated (950 rad) Rag 1–/– mice.
Statistical Analysis
Statistical analysis was performed using Prism software. Two-tailed unpaired
t tests were performed and p values <0.05were considered significant, and the
level of significance was indicated as *p < 0.05 and **p < 0.01. Differences in
tumor incidence were evaluated with the Mantel-Cox test.
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